Treatment of Epiretinal Membranes With Ranibizumab

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Queen's University
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• symptomatic idiopathic epiretinal membrane

Exclusion Criteria:

• vision worse than 6/18 and fit for surgery

• prior vitreoretinal surgery or injection

• diabetes

• any past or current form of retinal vein occlusion or neovascularization

• age-related macular degeneration

• other condition causing significant limitation of visual potential